Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nxera Pharma Co. Ltd. (4565:JPX), powered by AI.
Nxera Pharma Co. Ltd. is currently trading at ¥956. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Nxera Pharma Co. Ltd. on Alpha Lenz.
Nxera Pharma Co. Ltd.'s P/E ratio is -6.9.
“Nxera Pharma Co. Ltd. trades at a P/E of -6.9 (undervalued) with modest ROE of -19.3%. 3Y revenue CAGR of 23.9% highlights clear growth momentum.”
Ask for details →Nxera Pharma Co. Ltd. is a biotechnology and pharmaceutical company focused on developing innovative therapies for treating chronic and life-threatening conditions. The company's primary function is to research, develop, and commercialize drugs that address unmet medical needs, making significant strides in the fields of oncology, immunology, and metabolic disorders. With a commitment to scientific research and development, Nxera Pharma Co. Ltd. operates advanced laboratories and leverages cutting-edge technologies to bring breakthrough pharmaceuticals to the market. The company plays a pivotal role in the healthcare sector by introducing new treatment options, aiming to enhance patients' quality of life and contribute to better healthcare outcomes globally. Nxera Pharma Co. Ltd.'s impact extends across various demographics, providing healthcare solutions to both developed and emerging markets through strategic partnerships and collaborations with medical institutions. Its market significance is underscored by its ability to innovate rapidly in response to evolving health challenges, positioning it as a critical player in the global pharmaceutical industry.
“Nxera Pharma Co. Ltd. trades at a P/E of -6.9 (undervalued) with modest ROE of -19.3%. 3Y revenue CAGR of 23.9% highlights clear growth momentum.”
Ask for details →Nxera Pharma Co. Ltd. (ticker: 4565) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 389 employees. Market cap is $86.3B.
The current price is 956 with a P/E ratio of -6.89x and P/B of 1.41x.
ROE is -19.35% and operating margin is -28.57%. Annual revenue is $29.6B.